Over-eager docs prompt Abiomed to halt Protect II trial

December 6, 2010 by MassDevice staff

Abiomed Inc. touts the results from the Protect II study of its Impella cardiac assist device, despite halting the trial ahead of schedule.

ABMD logo

Over-ambitious doctors seem to have prompted Abiomed Inc. (NSDQ:ABMD) to close down a clinical trial of its flagship cardiac assist device.

The Danvers, Mass.-based company pulled the plug on the Protect II trial of its Impella 2.5 heart pump "based on a futility determination at the planned interim analysis regarding the primary end-point, which the company views as likely to be due to unanticipated confounding variables related to the use of rotational atherectomy," according to a press release.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.